Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Chemoradiotherapy in Advanced Oral Cavity SCC
NCT05749042Phase 2Unknown
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in oral cavity squamous cell carcinoma (OCSCC) (2 arms). Primary endpoints: Progression Free Survival at 24 months and Objective Response Rate at 24 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT05749042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749042.